Related Experiment Video
Updated: Jun 21, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
Published on: April 26, 2024
Tackling insomnia: diagnostic and treatment issues in primary care
Andrew G Israel1, Joseph A Lieberman
1University of California, San Diego, School of Medicine, USA.
Abstract:
Primary care physicians are often the first healthcare providers to encounter insomnia in their patients. However, they face many obstacles to diagnosis and treatment of insomnia that stem from patient- and physician-related factors. During consultations, most patients do not mention their sleep difficulties because they believe that insomnia is a trivial concern that does not have serious health consequences. Physicians also face diagnostic obstacles related to conflicting or vague diagnostic definitions, office-based time constraints, and a lack of training in sleep medicine in medical school and residency programs. Once a diagnosis is made, initiating appropriate treatment is also complicated because of outdated treatment guidelines and US Food and Drug Administration prescribing constraints. These factors may have contributed to the perception that there are no good treatment options for insomnia and that all available medications have a poor risk-benefit ratio. For example, benzodiazepines are known to carry a risk of tolerance and abuse. Until recently, few long-term data were available on the safety and efficacy of current agents, which may have contributed to reticence to treat chronic insomnia. Furthermore, there is limited evidence that treating insomnia is associated with improved patient outcomes, and this may have discouraged active treatment programs for insomnia. Increased awareness that insomnia can precede and exacerbate coexisting illnesses, including depression and chronic pain syndromes, is needed. As data emerge from recent clinical trials with newer, promising nonbenzodiazepine medications, it should become easier for primary care physicians to take a proactive role in diagnosing and treating insomnia and thus improve patient functioning.
More Related Videos
04:34Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
Published on: February 17, 2023
04:53Acupoint Application Combined with Ear Plaster Therapy for Treating Sleep Disorders with Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Published on: October 18, 2024
Related Concept Videos
Management of Insomnia
Insomnia
Multiple factors contribute...
Sleepwalking and Sleep Talking
Factors that increase the likelihood of sleepwalking include sleep deprivation and alcohol consumption. Contrary to common beliefs, it is safe...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Substance Use Disorders Affecting Sleep
Understanding the concepts of physical dependence,...
Sedatives and Hypnotics: Overview
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...